Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 11/2014

01.11.2014 | Research Article

Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression

verfasst von: Tao Yang, Xiao-Na Li, Li Li, Qi-Mei Wu, Peng-Zhi Gao, Hong-Lei Wang, Wei Zhao

Erschienen in: Tumor Biology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Sox17, an antagonist of canonical Wnt/β-catenin signaling, inhibits several malignant carcinogenesis and progression. However, little is known about Sox17 in hepatocellular carcinoma (HCC). Here, we found that Sox17 is downregulated in HCC tissue. Furthermore, Sox17 inhibits cell proliferation and migration in HCC. KIF14, a member of kinesin superfamily protein (KIFs), is an oncogene in a variety of malignant tumors including HCC. We demonstrated that Sox17 is negatively related to KIF14 expression in HCC tissue and Sox17 inhibits HCC cell proliferation and migration by transcriptional downregulation of KIF14 expression. Our results may provide a strategy for blocking HCC carcinogenesis and progression.
Literatur
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
3.
Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 2007;356:1545–59.PubMedCrossRef
4.
Kern MA, Breuhahn K, Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv Cancer Res. 2002;86:67–112.PubMedCrossRef
5.
Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46.PubMedCrossRef
6.
Kim I, Saunders TL, Morrison SJ. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell. 2007;130:470–83.PubMedCentralPubMedCrossRef
7.
Park KS, Wells JM, Zorn AM, Wert SE, Whitsett JA. Sox17 influences the differentiation of respiratory epithelial cells. Dev Biol. 2006;294:192–202.PubMedCrossRef
8.
Sohn J, Natale J, Chew LJ, Belachew S, Cheng Y, Aguirre A, et al. Identification of sox17 as a transcription factor that regulates oligodendrocyte development. J Neurosci Off J Soc Neurosci. 2006;26:9722–35.CrossRef
9.
Matsui T, Kanai-Azuma M, Hara K, Matoba S, Hiramatsu R, Kawakami H, et al. Redundant roles of sox17 and sox18 in postnatal angiogenesis in mice. J Cell Sci. 2006;119:3513–26.PubMedCrossRef
10.
Nakajima-Takagi Y, Osawa M, Oshima M, Takagi H, Miyagi S, Endoh M, et al. Role of sox17 in hematopoietic development from human embryonic stem cells. Blood. 2013;121:447–58.PubMedCrossRef
11.
Choi E, Kraus MR, Lemaire LA, Yoshimoto M, Vemula S, Potter LA, et al. Dual lineage-specific expression of sox17 during mouse embryogenesis. Stem Cells. 2012;30:2297–308.PubMedCentralPubMedCrossRef
12.
Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical wnt antagonist sry-box containing gene 17 in colorectal cancer. Cancer Res. 2008;68:2764–72.PubMedCentralPubMedCrossRef
13.
Liu Y, Asakura M, Inoue H, Nakamura T, Sano M, Niu Z, et al. Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells. Proc Natl Acad Sci U S A. 2007;104:3859–64.PubMedCentralPubMedCrossRef
14.
Fu DY, Wang ZM, Li C, Wang BL, Shen ZZ, Huang W, et al. Sox17, the canonical wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat. 2010;119:601–12.PubMedCrossRef
15.
Jia Y, Yang Y, Liu S, Herman JG, Lu F, Guo M. Sox17 antagonizes wnt/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics Off J DNA Methylation Soc. 2010;5:743–9.CrossRef
16.
Yang H, Lee S, Kim K, Yang Y, Kim JH, Adams RH, et al. Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice. J Clin Invest. 2013;123:418–31.PubMedCentralPubMedCrossRef
17.
Yin D, Jia Y, Yu Y, Brock MV, Herman JG, Han C, et al. Sox17 methylation inhibits its antagonism of wnt signaling pathway in lung cancer. Discov Med. 2012;14:33–40.PubMedCentralPubMed
18.
Combes P, Planche V, Eymard-Pierre E, Sarret C, Rodriguez D, Boespflug-Tanguy O, et al. Relevance of sox17 variants for hypomyelinating leukodystrophies and congenital anomalies of the kidney and urinary tract (cakut). Ann Hum Genet. 2012;76:261–7.PubMedCrossRef
19.
Ye YW, Wu JH, Wang CM, Zhou Y, Du CY, Zheng BQ, et al. Sox17 regulates proliferation and cell cycle during gastric cancer progression. Cancer Lett. 2011;307:124–31.PubMedCrossRef
20.
Oishi Y, Watanabe Y, Yoshida Y, Sato Y, Hiraishi T, Oikawa R, et al. Hypermethylation of sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2012;33:383–93.CrossRef
21.
Hirokawa N, Noda Y, Tanaka Y, Niwa S. Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol. 2009;10:682–96.PubMedCrossRef
22.
Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol. 2005;15:467–76.PubMedCrossRef
23.
24.
Yu Y, Feng YM. The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. Cancer. 2010;116:5150–60.PubMedCrossRef
25.
Carleton M, Mao M, Biery M, Warrener P, Kim S, Buser C, et al. RNA interference-mediated silencing of mitotic kinesin kif14 disrupts cell cycle progression and induces cytokinesis failure. Mol Cell Biol. 2006;26:3853–63.PubMedCentralPubMedCrossRef
26.
Ahmed SM, Theriault BL, Uppalapati M, Chiu CW, Gallie BL, Sidhu SS, et al. Kif14 negatively regulates rap1a-radil signaling during breast cancer progression. J Cell Biol. 2012;199:951–67.PubMedCentralPubMedCrossRef
27.
Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, Nigg EA, et al. Kif14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol. 2006;172:363–72.PubMedCentralPubMedCrossRef
28.
Madhavan J, Coral K, Mallikarjuna K, Corson TW, Amit N, Khetan V, et al. High expression of kif14 in retinoblastoma: association with older age at diagnosis. Invest Ophthalmol Vis Sci. 2007;48:4901–6.PubMedCrossRef
29.
Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL. Kif14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:3229–34.CrossRef
30.
Corson TW, Gallie BL. Kif14 mrna expression is a predictor of grade and outcome in breast cancer. Int J Cancer J Int du Cancer. 2006;119:1088–94.CrossRef
31.
Theriault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int J Cancer J int du Cancer. 2012;130:1844–54.CrossRef
32.
Wang Q, Wang L, Li D, Deng J, Zhao Z, He S, et al. Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. Cancer Epidemiol. 2013;37:79–84.PubMedCrossRef
33.
Madhavan J, Mitra M, Mallikarjuna K, Pranav O, Srinivasan R, Nagpal A, et al. Kif14 and e2f3 mrna expression in human retinoblastoma and its phenotype association. Mol Vis. 2009;15:235–40.PubMedCentralPubMed
34.
Yang T, Zhang XB, Zheng ZM. Suppression of kif14 expression inhibits hepatocellular carcinoma progression and predicts favorable outcome. Cancer Sci. 2013;104:552–7.PubMedCrossRef
35.
Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, et al. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer J Int du Cancer. 2008;123:2808–15.CrossRef
36.
Marinescu VD, Kohane IS, Riva A. Mapper: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics. 2005;6:79.PubMedCentralPubMedCrossRef
37.
Corson TW, Huang A, Tsao MS, Gallie BL. Kif14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene. 2005;24:4741–53.PubMedCrossRef
38.
Theriault BL, Basavarajappa HD, Lim H, Pajovic S, Gallie BL, Corson TW. Transcriptional and epigenetic regulation of kif14 overexpression in ovarian cancer. PLoS One. 2014;9:e91540.PubMedCentralPubMedCrossRef
39.
Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, et al. Induction and down-regulation of sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology. 2009;137:1346–57.PubMedCrossRef
40.
Wu Y, Li J, Sun CY, Zhou Y, Zhao YF, Zhang SJ. Epigenetic inactivation of the canonical wnt antagonist secreted frizzled-related protein 1 in hepatocellular carcinoma cells. Neoplasma. 2012;59:326–32.PubMedCrossRef
Metadaten
Titel
Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression
verfasst von
Tao Yang
Xiao-Na Li
Li Li
Qi-Mei Wu
Peng-Zhi Gao
Hong-Lei Wang
Wei Zhao
Publikationsdatum
01.11.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 11/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2398-7

Weitere Artikel der Ausgabe 11/2014

Tumor Biology 11/2014 Zur Ausgabe

Research Article

FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway

Research Article

Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization

Research Article

TES was epigenetically silenced and suppressed the epithelial–mesenchymal transition in breast cancer

Research Article

Relationship between IL-10 expression and prognosis in patients with primary breast cancer

Review

New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia

Research Article

Expression and clinical significance of microRNA-152 in supragalottic laryngeal carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise